| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Bioxcel Therapeutics, Inc. (BTAI) has 11 insiders with recent SEC Form 4 filings, including 7 buys and 21 sells. BTAI is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 17.0K | $20.2K | - | |
| Dir | 17.0K | $20.2K | - | |
| Dir | 17.0K | $20.2K | - | |
| Dir | 17.0K | $20.2K | - | |
| Dir | 17.0K | $20.2K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2021 | Yocca Frank88 | Chief Scientific Officer | Sell | 15,000 | $57.68 | $865,153.12 | -2.7% | |
| Feb 1, 2021 | Steinhart Richard I87 | Chief Financial Officer | Sale+OE | 3,750 | $48.15 | $180,562.50 | -71.4% | |
| Jan 25, 2021 | Yocca Frank88 | Chief Scientific Officer | Sale+OE | 15,000 | $48.39 | $725,814.28 | -3.8% | |
| Jan 19, 2021 | O'Neill Vincent86 | Chief Medical Officer | Sale+OE | 25,000 | $49.47 | $1,236,719.14 | -47.1% | |
| Dec 28, 2020 | O'Neill Vincent86 | Chief Medical Officer | Sale+OE | 25,000 | $51.45 | $1,286,156.68 | -58.6% | |
| Aug 23, 2019 | Mueller Peter | Director | Buy | 1,554 | $9.34 | $14,514.36 | +0.9% | |
| Aug 22, 2019 | Mueller Peter | Director | Buy | 8,446 | $8.74 | $73,840.18 | +2.7% | |
| Aug 16, 2019 | Mehta Vimal92 | CEO, President And Secretary | Buy | 974 | $8.89 | $8,658.86 | +10.8% | |
| Aug 15, 2019 | Mehta Vimal92 | CEO, President &Secretary | Buy | 2,983 | $8.64 | $25,780.27 | +24.1% | |
| Aug 13, 2019 | Mehta Vimal92 | CEO, President &Secretary | Buy | 1,000 | $8.75 | $8,750.00 | +20.0% |